Design of Patient Access Schemes in the UK: Influence of health technology assessment by the National Institute for Health and Clinical Excellence

Applied Health Economics and Health Policy

Volumn 9, Issue 4, 2011, Pages 209-215

  Jarosławski, Szymon ^a   Toumi, Mondher ^b  

^a CREATIV CEUTICAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Health services accessibility

Indexed keywords

BORTEZOMIB; CERTOLIZUMAB PEGOL; CETUXIMAB; DOCETAXEL; ERLOTINIB; GEFITINIB; LENALIDOMIDE; RANIBIZUMAB; SUNITINIB; TRABECTEDIN; USTEKINUMAB;

ARTICLE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; EXUDATIVE MACULAR DEGENERATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MEDICAL DOCUMENTATION; MULTIPLE MYELOMA; NATIONAL HEALTH SERVICE; PATIENT ACCESS SCHEME; PATIENT RIGHT; PROCESS DESIGN; PSORIASIS; RHEUMATOID ARTHRITIS; SOFT TISSUE SARCOMA; UNITED KINGDOM;

COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; GREAT BRITAIN; HUMANS; NATIONAL HEALTH PROGRAMS; RELATIVE VALUE SCALES;

EID: 79959399115     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11592960-000000000-00000     Document Type: Article

References (12)

1. Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ 2010 Jun 3; 340: c1672
2. McCabe C, Chilcott J, Claxton K, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ 2010 Jun 3; 340: c1786
3. Sudlow CL, Counsell CE. Problems with UK governments risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003 Feb 15; 326 (7385): 388-92 (Pubitemid 36241480)
4. House of Commons Health Committee. Fourth report: top up fees. Para 118. London: 2009May 12 [online]. Available from URL: http://www.publications. parliament.uk/pa/cm200809/ cmselect/cmhealth/194i/194i02.htm [Accessed 2010 Nov 26]
5. Department of Health. The Pharmaceutical Price Regulation Scheme. London: Department of Health, 2008Dec 11 [online]. Available from URL: http://www.dh.gov.uk/en/Publications andstatistics/Publications/ PublicationsPolicyAndGuidance/ DH-091825 [Accessed 2010 Nov 26]
6. Thorp H, Hughes C. Trends in NHS funding: patient access schemes. Clin Pharmacist 2010 Oct; 2 (9): 319, 321-2
7. National Institute for Health and Clinical Excellence. List of patient access schemes approved as part of a NICE appraisal. London: NICE, 2010 [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/paslu/ ListOfPatientAccessSchemesApprovedAsPartOfANICEA ppraisal.jsp [Accessed 2011 Mar 16]
8. Towse A. Value based pricing, research and development, and patient access schemes: will the United Kingdom get it right or wrong? Br J Clin Pharmacol 2010 Sep; 70 (3): 360-6
9. National Institute for Health and Clinical Excellence. Find guidance [online]. Available from URL: http://guidance. nice.org.uk [Accessed 2010 Dec 31]
10. Williamson S. A report into the uptake of patient access schemes in the NHS. Cancer Network Pharmacist Forum, 2009 Nov [online]. Available from URL: http://www.bo pawebsite.org/contentimages/publications/Report-into-Up take-of-Patient-Access-Schemes-8-11-09.pdf [Accessed 2010 Nov 26]
11. Chapman S, Reeve E, Rajaratnam G, et al. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. BMJ 2003 Mar 29; 326 (7391): 707-9 (Pubitemid 36390459)
12. National Institute for Health and Clinical Excellence. Process for advising on the feasibility of implementing a patient access scheme: interim. London: NICE, 2009 Sep [online]. Available from URL: http://www.nice.org.uk/ media/FCC/CC/PASLU ProcessGuide.pdf [Accessed 2010 Nov 26]